Annex A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EMA Number 
(Invented) 
name 
Strength 
Pharmaceutical 
Form 
Route of 
Administration 
Immediate 
Packaging 
EU/1/21/1566/001 
EU/1/21/1566/002 
EU/1/21/1566/003 
EU/1/21/1566/004 
Bylvay   
Bylvay   
Bylvay   
Bylvay   
200 µg 
400 µg 
600 µg 
1200 µg 
Capsule, hard 
Capsule, hard 
Capsule, hard 
Capsule, hard 
Oral use 
Oral use 
Oral use 
Oral use 
Bottle (HDPE) 
Bottle (HDPE) 
Bottle (HDPE) 
Bottle (HDPE) 
Pack size 
30 capsules  
30 capsules  
30 capsules  
30 capsules  
 
 
 
 
 
 
Conclusions on the granting of the marketing authorisation under exceptional circumstances 
presented by the European Medicines Agency 
Annex IV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions presented by the European Medicines Agency on: 
•  Marketing authorisation under exceptional circumstances 
The CHMP having considered the application is of the opinion that the risk-benefit balance is favourable 
to recommend the granting of the marketing authorisation under exceptional circumstances as further 
explained in the European Public Assessment Report. 
 
 
 
